TXN and cancer: Although the general significance of these in vitro data in the context of cancer treatment is limited, they strongly support the importance of an anticancer therapy based on a combined treatment of Sorafenib with inhibitors of the Trx system or other prooxidant agents for advanced HCC and encourage the undertaking of further research on this ground.